J&J takes Au­robindo to court over po­ten­tial Er­lea­da gener­ic

Since snag­ging a first ap­proval in prostate can­cer back in 2018, John­son & John­son has been work­ing to make Er­lea­da a block­buster fran­chise. Now that means fight­ing off a po­ten­tial gener­ic from Au­robindo.

A group of plain­tiffs, in­clud­ing J&J’s Janssen unit and the Sloan Ket­ter­ing In­sti­tute for Can­cer Re­search, filed a law­suit against Au­robindo on Thurs­day ac­cus­ing it of ap­ply­ing to mar­ket an Er­lea­da copy­cat be­fore five patents are up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER